Catalyst Pharmaceuticals (CPRX) Free Cash Flow Growth (1y) (2011 - 2026)
Catalyst Pharmaceuticals (CPRX) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 137.65% |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | -0.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.80% |
| Dec 31, 2025 | -36.63% |
| Sep 30, 2025 | -55.33% |
| Jun 30, 2025 | 11.15% |
| Mar 31, 2025 | 89.25% |
| Dec 31, 2024 | 27.42% |
| Sep 30, 2024 | 61.13% |
| Jun 30, 2024 | 108.51% |
| Mar 31, 2024 | 164.47% |
| Dec 31, 2023 | 38.62% |
| Sep 30, 2023 | 9.11% |
| Jun 30, 2023 | 17.42% |
| Mar 31, 2023 | 41.50% |
| Dec 31, 2022 | 109.44% |
| Sep 30, 2022 | 90.86% |
| Jun 30, 2022 | 67.10% |
| Mar 31, 2022 | 192.04% |
| Dec 31, 2021 | 46.01% |
| Sep 30, 2021 | 88.97% |
| Jun 30, 2021 | 18.16% |